J&J Pays $25 Million to End Antitrust Case Over Autoimmune Drug

Johnson & Johnson affiliates will pay $25 million to end antitrust litigation over their alleged scheme to delay generic versions of the anti-inflammatory Remicade, a biologic drug used to treat autoimmune disorders, according to a federal court filing in Philadelphia.

The settlement, disclosed April 15, would resolve class action claims on behalf of pension funds and other indirect Remicade purchasers that accused J&J and its Janssen unit of using exclusionary contracts and product bundling to prevent certain insurers from covering Remicade “biosimilars,” as generic versions of biologic drugs are known.

The agreement requires the approval of Judge Karen S. Marston, ...